APX001A In Vitro Activity against Contemporary Blood Isolates and Candida auris Determined by the EUCAST Reference Method

In Vivo Pharmacokinetics and Pharmacodynamics of APX001 against Candida spp. in a Neutropenic Disseminated Candidiasis Mouse Model

(2018) Miao Zhao et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In Vitro and In Vivo Evaluation of the Antifungal Activity of APX001A/APX001 against Candida auris

(2018) Christopher L. Hager et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

A multicentre study of antifungal susceptibility patterns among 350 Candida auris isolates (2009–17) in India: role of the ERG11 and FKS1 genes in azole and echinocandin resistance

(2018) Anuradha Chowdhary et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Molecular basis of antifungal drug resistance in yeasts

(2017) Florent Morio et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Update from a 12-Year Nationwide Fungemia Surveillance: Increasing Intrinsic and Acquired Resistance Causes Concern

(2017) K. M. T. Astvad et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Candida auris: A rapidly emerging cause of hospital-acquired multidrug-resistant fungal infections globally

(2017) Anuradha Chowdhary et al.   PLoS Pathogens

Simultaneous Emergence of Multidrug-ResistantCandida aurison 3 Continents Confirmed by Whole-Genome Sequencing and Epidemiological Analyses

(2016) Shawn R. Lockhart et al.   CLINICAL INFECTIOUS DISEASES

EUCAST technical note on isavuconazole breakpoints for Aspergillus, itraconazole breakpoints for Candida and updates for the antifungal susceptibility testing method documents

(2016) M.C. Arendrup et al.   CLINICAL MICROBIOLOGY AND INFECTION

Multidrug-resistant Candida auris : ‘new kid on the block’ in hospital-associated infections?

(2016) A. Chowdhary et al.   JOURNAL OF HOSPITAL INFECTION

The Investigational Agent E1210 Is Effective in Treatment of Experimental Invasive Candidiasis Caused by Resistant Candida albicans

(2014) Nathan P. Wiederhold et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Efficacy of Oral E1210, a New Broad-Spectrum Antifungal with a Novel Mechanism of Action, in Murine Models of Candidiasis, Aspergillosis, and Fusariosis

(2011) Katsura Hata et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In VitroActivity of E1210, a Novel Antifungal, against Clinically Important Yeasts and Molds

(2011) Mamiko Miyazaki et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In vitro activity of a novel broad-spectrum antifungal, E1210, tested against Candida spp. as determined by CLSI broth microdilution method

(2011) Michael A. Pfaller et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Pre-clinical development of antifungal susceptibility test methods for the testing of the novel antifungal agent E1210 versus Candida: comparison of CLSI and European Committee on Antimicrobial Susceptibility Testing methods

(2011) M. A. Pfaller et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Variation in Candida spp. distribution and antifungal resistance rates among bloodstream infection isolates by patient age: report from the SENTRY Antimicrobial Surveillance Program (2008–2009)

(2010) Michael A. Pfaller et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE